Literature DB >> 31090589

Treat-to-target in axial spondyloarthritis: gold standard or fools' gold?

Pedro M Machado1,2,3, Atul Deodhar4.   

Abstract

PURPOSE OF REVIEW: Treat-to-target (T2T) is an emerging management strategy in axial spondyloarthritis (axSpA). The concept was originally based on evidence from other chronic conditions, such as hypertension, diabetes and hypothyroidism, as well as some rheumatic diseases, such as rheumatoid arthritis and gout. The purpose of this review is to discuss the arguments against and in favour of adopting a T2T strategy in the management of axSpA. RECENT
FINDINGS: International groups have recommended a T2T strategy in axSpA. Inactive disease according to the Ankylosing Spondylitis Disease Activity Score (ASDAS) has been suggested as a potential target. Achievement of ASDAS inactive disease has been associated with less progression of radiographic damage in several studies. Evidence for the benefit of a T2T approach has been published in psoriatic arthritis, a form of spondyloarthritis.
SUMMARY: Observational evidence suggests that a T2T approach might be beneficial in axSpA. However, data from a prospective randomized study proving the efficacy of a T2T strategy compared to routine care are still lacking. Moreover, the cost-effectiveness of such strategy in clinical practice also needs to be tested. The target will need to be useful and feasible in both clinical practice and clinical trials.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31090589     DOI: 10.1097/BOR.0000000000000625

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  5 in total

Review 1.  Value-Based Healthcare in Rheumatology: Axial Spondyloarthritis and Beyond.

Authors:  David F L Liew; Jonathan Dau; Philip C Robinson
Journal:  Curr Rheumatol Rep       Date:  2021-04-28       Impact factor: 4.592

2.  Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study.

Authors:  Liz Van Rossen; Antoni Chan; Annie Gilbert; Karl Gaffney; Claire Harris; Pedro M Machado; Liliana R Santos; Raj Sengupta; Paul Basset; Andrew Keat
Journal:  Rheumatol Adv Pract       Date:  2020-05-13

3.  Predictors of not Achieving Remission or Low Disease Activity in Axial Spondyloarthritis Patients from Middle Eastern Countries: A Prospective, Multicenter, Real-world Study.

Authors:  Jamal Ali Al-Saleh; Majid Abi Saab; Ahmed Negm; Farida Balushi; Rajaie Namas; Nelly Ziade
Journal:  Oman Med J       Date:  2022-05-31

4.  Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA.

Authors:  Tomas Milota; Jana Hurnakova; Karel Pavelka; Zlatuse Kristkova; Lucie Nekvindova; Rudolf Horvath
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-03-17       Impact factor: 5.346

5.  Treat-to-target in axial spondyloarthritis: an observational study in daily practice.

Authors:  Esther Beckers; Annelies Boonen; Casper Webers; Peter Ten Klooster; Harald Vonkeman; Monique Efdé; Astrid van Tubergen
Journal:  Rheumatology (Oxford)       Date:  2022-04-11       Impact factor: 7.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.